Metastatic atypical renal tumour with metanephric characteristics treated with Sunitinib

H. Mohammad; K. Madsen; O. Graumann; A. C. Loya; N. Jensen; R. H. Dahlrot

doi:10.1016/j.eucr.2021.101880

Metastatic atypical renal tumour with metanephric characteristics treated with Sunitinib

H. Mohammad^*, K. Madsen, O. Graumann, A. C. Loya, N. Jensen, R. H. Dahlrot

^*Corresponding author for this work

Research output: Contribution to journal › Journal article › Research › peer-review

1 Citation (Scopus)

11 Downloads (Pure)

Abstract

Metanephric Adenoma (MA) is a rare and unclassifiable renal tumour with sparse reported clinical and morphological features. Generally MA's have a benign course without recurrence after nephrectomy, however a few cases received oncological treatment due to malignant progression. We present a 42-year-old woman who years after an initial nephrectomy developed several processes and biopsy confirmed recurrence of MA. Sunitinib was given for only two weeks, as she developed side-effects and currently the patient undergoes control scans with only minimal growth of the processes. This is the first case of MA treated with Tyrosin-Kinase-Inhibitor.

Original language	English
Article number	101880
Journal	Urology Case Reports
Volume	40
Number of pages	4
ISSN	2214-4420
DOIs	https://doi.org/10.1016/j.eucr.2021.101880
Publication status	Published - 2022

Keywords

Metanephric adenoma
Tyrosine kinase inhibitor
Oncology
Renal tumour
ADENOMA

Access to Document

10.1016/j.eucr.2021.101880Licence: CC BY-NC-ND

FulltextFinal published version, 4.54 MBLicence: CC BY-NC-ND

Cite this

@article{afe1a29b04ed4babba53ebc8129cc171,

title = "Metastatic atypical renal tumour with metanephric characteristics treated with Sunitinib",

abstract = "Metanephric Adenoma (MA) is a rare and unclassifiable renal tumour with sparse reported clinical and morphological features. Generally MA's have a benign course without recurrence after nephrectomy, however a few cases received oncological treatment due to malignant progression. We present a 42-year-old woman who years after an initial nephrectomy developed several processes and biopsy confirmed recurrence of MA. Sunitinib was given for only two weeks, as she developed side-effects and currently the patient undergoes control scans with only minimal growth of the processes. This is the first case of MA treated with Tyrosin-Kinase-Inhibitor.",

keywords = "Metanephric adenoma, Tyrosine kinase inhibitor, Oncology, Renal tumour, ADENOMA",

author = "H. Mohammad and K. Madsen and O. Graumann and Loya, {A. C.} and N. Jensen and Dahlrot, {R. H.}",

year = "2022",

doi = "10.1016/j.eucr.2021.101880",

language = "English",

volume = "40",

journal = "Urology Case Reports",

issn = "2214-4420",

publisher = "Elsevier Saunders",

}

TY - JOUR

T1 - Metastatic atypical renal tumour with metanephric characteristics treated with Sunitinib

AU - Mohammad, H.

AU - Madsen, K.

AU - Graumann, O.

AU - Loya, A. C.

AU - Jensen, N.

AU - Dahlrot, R. H.

PY - 2022

Y1 - 2022

N2 - Metanephric Adenoma (MA) is a rare and unclassifiable renal tumour with sparse reported clinical and morphological features. Generally MA's have a benign course without recurrence after nephrectomy, however a few cases received oncological treatment due to malignant progression. We present a 42-year-old woman who years after an initial nephrectomy developed several processes and biopsy confirmed recurrence of MA. Sunitinib was given for only two weeks, as she developed side-effects and currently the patient undergoes control scans with only minimal growth of the processes. This is the first case of MA treated with Tyrosin-Kinase-Inhibitor.

AB - Metanephric Adenoma (MA) is a rare and unclassifiable renal tumour with sparse reported clinical and morphological features. Generally MA's have a benign course without recurrence after nephrectomy, however a few cases received oncological treatment due to malignant progression. We present a 42-year-old woman who years after an initial nephrectomy developed several processes and biopsy confirmed recurrence of MA. Sunitinib was given for only two weeks, as she developed side-effects and currently the patient undergoes control scans with only minimal growth of the processes. This is the first case of MA treated with Tyrosin-Kinase-Inhibitor.

KW - Metanephric adenoma

KW - Tyrosine kinase inhibitor

KW - Oncology

KW - Renal tumour

KW - ADENOMA

U2 - 10.1016/j.eucr.2021.101880

DO - 10.1016/j.eucr.2021.101880

M3 - Journal article

C2 - 34692420

VL - 40

JO - Urology Case Reports

JF - Urology Case Reports

SN - 2214-4420

M1 - 101880

ER -